Platelet-activating factor antagonists enhance intracellular degradation of amyloid-β$_{42}$ in neurons via regulation of cholesterol ester hydrolases

Charlotte Simmons$^1$, Victoria Ingham$^1$, Alun Williams$^2$ and Clive Bate$^1$*

Abstract

Introduction: The progressive dementia that is characteristic of Alzheimer’s disease is associated with the accumulation of amyloid-beta (Aβ) peptides in extracellular plaques and within neurons. Aβ peptides are targeted to cholesterol-rich membrane micro-domains called lipid rafts. Observations that many raft proteins undertake recycling pathways that avoid the lysosomes suggest that the accumulation of Aβ in neurons may be related to Aβ targeting lipid rafts. Here we tested the hypothesis that the degradation of Aβ by neurons could be increased by drugs affecting raft formation.

Methods: Primary neurons were incubated with soluble Aβ preparations. The amounts of Aβ$_{42}$ in neurons or specific cellular compartments were measured by enzyme-linked immunosorbent assay. The effects of drugs on the degradation of Aβ$_{42}$ were studied.

Results: Aβ$_{42}$ was targeted to detergent-resistant, low-density membranes (lipid rafts), trafficked via a pathway that avoided the lysosomes, and was slowly degraded by neurons (half-life was greater than 5 days). The metabolism of Aβ$_{42}$ was sensitive to pharmacological manipulation. In neurons treated with the cholesterol synthesis inhibitor squalestatin, less Aβ$_{42}$ was found within rafts, greater amounts of Aβ$_{42}$ were found in lysosomes, and the half-life of Aβ$_{42}$ was reduced to less than 24 hours. Treatment with phospholipase A$_2$ inhibitors or platelet-activating factor (PAF) antagonists had the same effects on Aβ$_{42}$ metabolism in neurons as squalestatin. PAF receptors were concentrated in the endoplasmic reticulum (ER) along with enzymes that constitute the cholesterol ester cycle. The addition of PAF to ER membranes triggered activation of cholesterol ester hydrolases and the release of cholesterol from stores of cholesterol esters. An inhibitor of cholesterol ester hydrolases (diethylumbelliferyl phosphate) also increased the degradation of Aβ$_{42}$ in neurons.

Conclusions: We conclude that the targeting of Aβ$_{42}$ to rafts in normal cells is a factor that affects its degradation. Critically, pharmacological manipulation of neurons can significantly increase Aβ$_{42}$ degradation. These results are consistent with the hypothesis that the Aβ-induced production of PAF controls a cholesterol-sensitive pathway that affects the cellular localization and hence the fate of Aβ$_{42}$ in neurons.
Introduction

The amyloid hypothesis of Alzheimer’s disease (AD) pathogenesis maintains that the primary event is the production of specific C-terminal amyloid-beta (Aβ) peptides following the abnormal proteolytic cleavage of the amyloid precursor protein [1]. Aβ oligomers demonstrate disease-specific accumulation in human brain and cerebrospinal fluid [2]. The accumulation of Aβ peptides leads to the subsequent disruption of neuronal processes, abnormal phosphorylation of tau [3], and synapse degeneration [4]. Currently, soluble Aβ42 oligomers are regarded as potent neurotoxins [5,6].

Neurodegeneration is preceded by the intraneuronal accumulation of Aβ [7,8]. The chronic nature of AD suggests that it is a slow accumulation of Aβ that triggers neurodegeneration and hence the clinical symptoms. Whereas the factors that affect the production of the Aβ have been studied extensively, the capacity of neurons to degrade Aβ once it has been formed has received less attention. Thus, the accumulation of Aβ within neurons may result from a slow rate of degradation. Aβ peptides can be degraded by proteases, including neprilysin [9], insulin [10], cathepsin B [11], and acyl peptide hydrolase [12]. The observation that Aβ was degraded more quickly in microglial cells than in neurons (unpublished data) raised the question of whether the rate of degradation of Aβ within neurons could be increased.

Studies that use synthetic Aβ preparations may be compromised by their propensity to self-aggregate into a wide variety of oligomer sizes and conformations. The polymorphic nature of Aβ aggregates suggests that there exist disease-relevant conformations of Aβ but that other conformations are less toxic [13,14]. It is difficult to control the size and conformation of synthetic Aβ42 oligomers in aqueous medium and consequently it is not clear which of the Aβ conformations are responsible for specific biological properties. To overcome this problem, conditioned media from 7PA2 cells (7PA2-CM) which contain naturally secreted Aβ oligomers [15] were used in this study. The Aβ oligomers secreted by these cells are sodium dodecyl sulphate (SDS)-stable, as are the Aβ oligomers found within the cerebrospinal fluid of patients with AD [16-18]. Although 7PA2-CM includes other amyloid precursor protein (APP) metabolites, including Aβ40 and p3, we decided to specifically measure Aβ42 peptides because of the close association of this isoform with disease.

Aβ42 peptides are found in detergent-resistant, cholesterol-dense membrane micro-domains which are commonly referred to as rafts [19-21]. Since many raft-associated proteins traffic through cells via recycling pathways that avoid the lysosomes [22,23], we hypothesized that targeting of Aβ42 to rafts caused it to avoid the lysosomes and degradation. Thus, the targeting of Aβ42 to rafts may contribute to their gradual accumulation within neurons and subsequently their toxic effects. In this study, non-toxic concentrations of Aβ42 were taken up by cultured neurons and targeted to detergent-resistant membranes (DRMs) (lipid rafts). As a consequence, it was slowly degraded and had a half-life of greater than 5 days. As the formation and function of lipid rafts is dependent upon the amount of cholesterol within cell membranes [24-26], the effects of the cholesterol synthesis inhibitor squalestatin [27] on the cellular targeting of Aβ42 were studied. Here, we show that, in neurons treated with squalestatin, significantly less Aβ42 was targeted to rafts and more was found within lysosomes. Consequently, in squalestatin-treated neurons, the half-life of Aβ42 was reduced to less than 24 hours. Such results indicate that the pharmacological manipulation of neurons can alter the clearance of Aβ42.

Methods

Primary neuronal cultures

Cortical neurons were prepared from the brains of mouse embryos (day 15.5). Neurons were plated at 10⁶ cells per well in six-well plates in Ham’s F12 containing 5% fetal calf serum for 2 hours. Cultures were shaken (600 rpm for 5 minutes), and non-adherent cells were removed by two washes in phosphate-buffered saline (PBS). Neurons were subsequently grown in neurobasal medium containing B27 components supplemented with 5 nM brain-derived nerve growth factor for 10 days. Immunohistochemistry showed that the cells were greater than 95% neurofilament-positive. Less than 3% stained for glial fibrillary acidic protein (astrocytes) or for F4/80 (microglial cells). Neurons were pre-treated with test compounds for 3 hours before the addition of Aβ preparations, and the amount of Aβ42 in treated neurons was measured at specific time points thereafter. All experiments were performed in accordance with European regulations (European community Council Directive, 1986, 56/609/EEC) and approved by the Royal Veterinary College ethics committee.

Cell extracts

Neurons were washed twice with PBS and homogenized in a buffer containing 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS, and mixed protease inhibitors (4-(2-Aminoethyl) benzencesulfonyl Fluoride hydrochloride (AEBSF), Aprotinin, Leupeptin, Bestatin, Pepstatin A, and E-46) (Sigma-Aldrich, St. Louis, MO, USA) at 10⁶ cells/mL. Nuclei and large fragments were removed by centrifugation (300 g for 5 minutes).

Isolation of detergent-resistant membranes

These membranes were isolated by their insolubility in non-ionic detergents as described [28]. Briefly, cells were...
homogenized in an ice-cold buffer containing 1% Triton X-100, 10 mM Tris-HCl, pH 7.2, 150 mM NaCl, 10 mM EDTA, and mixed protease inhibitors at 10⁶ cells/mL, and nuclei and large fragments were removed by centrifugation (300 g for 5 minutes at 4°C). The post-nuclear supernatant was incubated on ice (4°C) for 1 hour and centrifuged (16,000 g for 30 minutes at 4°C). The supernatant was reserved as the detergent-soluble membrane; the insoluble pellet was homogenized in an extraction buffer containing 10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS, and mixed protease inhibitors at 10⁶ cells/mL and was centrifuged (10 minutes at 16,000 g); and the soluble material was reserved as the DRM fraction.

Sucrose density isolation
Neurons were harvested with a Teflon scraper and collected at 800 g for 5 minutes. Cell pellets were homogenized in a buffer containing 250 mM sucrose, 10 mM Tris-HCl (pH 7.4), 1 mM EGTA, mixed protease inhibitors, and 1 mM dithiothreitol at 10⁶ cells/mL. Particulate membrane fragments and nuclei were removed by centrifugation (1,000 g for 5 minutes). Membranes were washed by centrifugation at 16,000 g for 10 minutes at 4°C and suspended in an ice-cold buffer containing 1% Triton X-100, 10 mM Tris-HCl pH 7.2, 150 mM NaCl, 10 mM EDTA. Sucrose solutions of 5%, 10%, 15%, 20%, 25%, 30%, and 40% were prepared and layered over each other. Solubilized membranes were added on top and centrifuged at 50,000 g for 18 hours at 4°C. Serial 1-mL aliquots were collected from the bottom of gradients.

Isolation of lysosomes
Lysosomes were isolated by using a lysosome enrichment kit designed for cultured cells in accordance with the instructions of the manufacturer (Pierce, Rockford, IL, USA). Briefly, treated cells were collected and homogenized in ice-cold lysosome enrichment reagents containing protease inhibitors (as above). The cell extract was overlaid on a discontinuous density gradient (OptiPrep™), serial 1-mL aliquots were collected from the bottom of gradients. Fractions were collected, washed three times in PBS (18,000 g for 30 minutes at 4°C), and solubilized in an extraction buffer containing 10 mM Tris-HCl pH 7.4, 100 mM NaCl, 10 mM EDTA, 0.5% Nonidet P-40, 0.5% sodium deoxycholate, 0.2% SDS, and protease inhibitors (as above). Samples were mixed with an equal volume of Laemmli buffer, boiled, and subjected to electrophoresis on a 15% polyacrylamide gel. Proteins were transferred onto a Hybond-P polyvinylidiene fluoride (PVDF) membrane by semi-dry blotting. Membranes were blocked by using 10% milk powder in PBS containing 0.2% Tween 20. Blots were probed with anti-lysosome-associated membrane protein 1 (LAMP-1) (Pharmingen, San Diego, CA, USA) followed by peroxidase-labelled anti-rabbit antibodies and visualized by using enhanced chemiluminescence.

Isolation of endoplasmic reticulum
Endoplasmic reticulum (ER) fractions were isolated from treated cells by using an ER preparation kit (Sigma-Aldrich) in accordance with the instructions of the manufacturer. Homogenized cell extracts were separated on a discontinuous density gradient (OptiPrep™). Serial 1-mL aliquots were collected from the bottom of gradients. Fractions were diluted 1:20 in carbonate buffer and distributed into Nunc Maxisorp immunoplates (Nunc, Roskilde, Denmark) overnight. Plates were blocked with 5% milk powder and probed with monoclonal antibody (mAb) reactive to the ER marker Grp 78 (Stressgen Biotechnology, Victoria, Canada), polyclonal anti-PAP receptor (Cayman Chemical Company, Ann Arbor, MI, USA), anti-cholesterol ester hydrolase (CEH) (LifeSpan BioSciences, Seattle, WA, USA), or anti-acyl-coenzyme A:cholesterol acyltransferase (ACAT) (Abcam, Cambridge, UK), followed by biotinylated anti-rabbit IgG (Sigma-Aldrich), extravidin-alkaline phosphatase (Sigma-Aldrich), and the addition of the substrate p-nitrophenyl phosphate (p-NPP), 1 ng/mL, diluted in diethanolamine buffer. Optical density was read in a spectrophotometer at 405 nm.

Cholesterol and protein content
Protein concentrations were measured by using a micro-BCA protein assay kit (Pierce). The amount of cholesterol was measured by using the Amplex Red cholesterol assay kit (Invitrogen, Carlsbad, CA, USA). Cholesterol was oxidized by cholesterol oxidase to yield hydrogen peroxide and ketones. The hydrogen peroxide reacts with 10-acetyl-3, 7-dihydroxyphenoxazine (Amplex Red) to produce highly fluorescent resorufin, which is measured by excitation at 550 nm and emission detection at 590 nm. Samples were incubated in the presence or absence of cholesterol esterase to determine the amounts of esterified cholesterol.

Drugs
Arachidonyl trifluoromethyl ketone (AACOCF₃), acetetyl salicylic acid, diethyllumelliferyl phosphate (DEUP), ginkgolide B, ibuprofen, platelet-activating factor (PAF), 1-O-Hexadecyl-2-acetyl-sn-glycerol-3-phospho-(N,N,N-tri-methyl)-hexanolamine (Hexa-PAF), methyl arachidonoyl fluorophosphonate (MAFP), acetetyl salicylic acid, ibuprofen, simvastatin, and squalene were all obtained from Sigma-Aldrich. Squalstatin was a gift from GlaxoSmithKline (Uxbridge, Middlesex, UK). Stock solutions were dissolved in ethanol or di-methyl sulphoxide and diluted.
in medium to obtain final working concentrations. Vehicle controls consisted of equivalent dilutions of ethanol or dimethyl sulphoxide in culture medium.

Preparation of Aβ-containing medium
Conditioned media (CM) from Chinese hamster ovary (CHO) cells stably transfected with a cDNA encoding APP<sub>751</sub> (referred to as 7PA2 cells) was cultured in Dulbecco’s modified Eagle’s medium with 10% fetal calf serum as described [15]. CM from these cells contains stable Aβ (7PA2-CM). 7PA2-CM was centrifuged at 100,000 × g for 4 hours at 4°C to remove cell debris and then passed through a 50-kDa filter (Sartorius, Goettingen, Germany) before use. To demonstrate Aβ species, concentrated 7PA2-CM was mixed 1:1 with (0.5% NP-40, 5 mM CHAPS, 50 mM Tris-HCl, pH 7.4, and mixed protease inhibitors) and separated by polyacrylamide gel electrophoresis (PAGE) under non-denaturing conditions. Proteins were transferred onto a Hybond-P PVDF membrane (Amersham Biotech, now part of GE Healthcare, Little Chalfont, Buckinghamshire, UK) by semi-dry blotting. Membranes were blocked by using 10% milk powder and incubated with mAb 6E10 reactive with amino acids 1 to 16 of human Aβ (Signet, part of Covance, Princeton, NJ, USA). Bound mAbs were detected with biotinylated anti-mouse IgG, extravidin-peroxidase, and enhanced chemiluminescence.

Size exclusion chromatography
7PA2-CM or brain extracts were concentrated by desalting columns (3-kDa filter; Sartorius) and injected into a Superdex 75 PC column (separates peptides ranging from 3 to 70 kDa) (GE Healthcare) and eluted at a rate of 0.2 mL/minute. Fractions were collected and tested by Aβ enzyme-linked immunosorbent assay (ELISA) (see below).

Sample preparation
To detach Aβ<sub>42</sub> from cellular binding proteins that could occlude specific epitopes, cell extracts (200 μL) were mixed with 500 μL of 70% formic acid and sonicated. A 50-μL aliquot was added to 450 μL of 1 M Tris-HCl with protease inhibitors (as above) and sonicated prior to addition to ELISA.

Synthetic Aβ
A peptide corresponding to amino acids 1 to 42 of Aβ (Aβ<sub>1-42</sub>) was obtained from Bachem (Bubendorf, Switzerland) and dissolved in hexafluoroisopropanol, lyophilized, and stored at −80°C. On the day of use, it was dissolved in dimethylsulphoxide at 1 mM, diluted in culture medium, and sonicated prior to addition to cells.

Aβ<sub>42</sub> enzyme-linked immunosorbent assay
Nunc Maxisorp immunoplates were coated with mAb 4G8 (epitope 17-24) (Covance) in carbonate buffer overnight. Plates were blocked with 5% milk powder in PBS-tween, and samples were applied. The detection antibody was an Aβ<sub>42</sub> selective rabbit mAb BA3-9 (Covance) followed by biotinylated anti-rabbit IgG (Sigma-Aldrich). Total Aβ was visualized by addition of the substrate (pNPP) 1 ng/mL, diluted in diethanolamine buffer, and optical density was read in a spectrophotometer at 405 nm.

Statistical methods
Differences between treatment groups were assessed by using Student t tests.

Results
Squalestatin increased the degradation of Aβ<sub>42</sub>
The amount and distribution of cholesterol are recognized as factors that affect the progression of AD [29,30]. As squalestatin reduced the cholesterol content of cultured neurons [31], the fate of Aβ<sub>42</sub> in squalestatin-treated neurons was examined. Treatment with 200 nM squalestatin for 24 hours reduced the cholesterol content of neurons from 519 ng cholesterol/10<sup>6</sup> cells ± 48 to 369 ng ± 66, n = 6, P < 0.05, without affecting neuronal viability as measured by thiazolyl blue tetrazolium (MTT). Both treated and untreated neurons were subsequently incubated with 7PA2-CM containing 10 nM Aβ<sub>42</sub>, a mixture of monomers, dimers, trimers, and tetramers as shown in Figure 1A. An analysis of concentrated 7PA2-CM by size exclusion chromatography also showed that it contained three main peaks corresponding to monomers, dimers, and trimers (Figure 1B). The concentrations of Aβ<sub>42</sub> used did not affect neuronal survival during the 5-day incubation period. In control neurons, Aβ<sub>42</sub> had a half-life of greater than 5 days, whereas in squalestatin-treated neurons, the half-life of Aβ<sub>42</sub> was reduced to less than 24 hours (Figure 1C). Aβ<sub>42</sub> was not detected in cell supernatants, suggesting that the Aβ<sub>42</sub> had been digested rather than secreted from neurons. Experiments performed using synthetic Aβ<sub>1-42</sub> showed that it behaved like the cell-derived Aβ<sub>42</sub>; it had a half-life of greater than 5 days in untreated neurons and a much shorter half-life in squalestatin-treated neurons (Figure 1D).

Similar results were obtained in neurons that had been treated with 1 μM simvastatin, a clinically approved hydroxymethyl glutaryl coenzyme A reductase inhibitor that also reduced cellular cholesterol levels. As cholesterol depletion has been demonstrated to affect the expression of some receptors, including the cellular prion protein [32] and acetylcholine receptors [33], the possibility that it reduced the binding of Aβ<sub>42</sub> to neurons was explored. There were no significant differences in the
For 2 days, were found within DRMs, observations that are consistent with reports that membrane-bound Aβ was recruited into lipid rafts [19-21,34,35]. In squalestatin-treated neurons, significantly less Aβ42 was found within DRMs (Figure 2A). Since many of the proteins that are targeted to lipid rafts traffic via a recycling pathway that avoids the lysosomes [23,36], an organelle fractionation technique was used to examine the targeting of Aβ42 to lysosomes. Organelles from neurons were separated on a density gradient, and lysosomes were identified by using immunoblots for lysosome-associated antigen 1 (LAMP-1), a marker of late endosomes/lysosomes. LAMP-1 was enriched within fractions 4 to 6, which were subsequently pooled to represent the lysosomes (Figure 2B). Firstly, we showed that treatment with 200 nM squalestatin did not affect the amount of the LAMP-1 found in neurons (Figure 2C). Next, treated neurons were incubated with 10 nM Aβ42 for 2 hours, and the amount of Aβ42 in lysosomes was measured. The amounts of Aβ42 in lysosomes from squalestatin-treated neurons were significantly higher than the amounts of Aβ42 in lysosomes from control neurons (Figure 2D).

**Squalestatin altered the distribution of Aβ42 in neurons**

Next, we looked at the distribution of Aβ42 within neurons. In control neurons incubated with 10 nM Aβ42 for 2 hours, most Aβ42 was found within DRMs, observations that are consistent with reports that membrane-bound Aβ was recruited into lipid rafts [19-21,34,35]. In squalestatin-treated neurons, significantly less Aβ42 was found within DRMs (Figure 2A). Since many of the proteins that are targeted to lipid rafts traffic via a recycling pathway that avoids the lysosomes [23,36], an organelle fractionation technique was used to examine the targeting of Aβ42 to lysosomes. Organelles from neurons were separated on a density gradient, and lysosomes were identified by using immunoblots for lysosome-associated antigen 1 (LAMP-1), a marker of late endosomes/lysosomes. LAMP-1 was enriched within fractions 4 to 6, which were subsequently pooled to represent the lysosomes (Figure 2B). Firstly, we showed that treatment with 200 nM squalestatin did not affect the amount of the LAMP-1 found in neurons (Figure 2C). Next, treated neurons were incubated with 10 nM Aβ42 for 2 hours, and the amount of Aβ42 in lysosomes was measured. The amounts of Aβ42 in lysosomes from squalestatin-treated neurons were significantly higher than the amounts of Aβ42 in lysosomes from control neurons (Figure 2D).

**Squalene reversed the effect of squalestatin on the cellular distribution of Aβ42**

One explanation of these results is that the squalestatin-induced reduction in cholesterol disrupts the formation of lipid rafts that direct Aβ42 into a pathway that avoids the lysosomes. This hypothesis was tested by incubating neurons with combinations of squalestatin and squalene. The addition of 5 μM squalene alone did not increase cholesterol concentrations above those of control cells (527 ng cholesterol/10^6 cells ± 28 to 519 ng ± 48, n = 6, P = 0.74), but the addition of 5 μM squalene reversed the effects of 200 nM squalestatin on cellular cholesterol concentrations (496 ng cholesterol/10^6 cells ± 45 to 369 ng ± 66, n = 6, P <0.05). The addition of 5 μM squalene also reversed the effects of 200 nM squalestatin on the trafficking of Aβ42; the amount of Aβ42 in DRMs was significantly lower and the amount in lysosomes significantly higher in neurons treated with squalestatin when compared with neurons treated with a combination of squalestatin and squalene. The addition of 5 μM squalene did not affect the amount of the LAMP-1 found in neurons (Figure 2C). Next, treated neurons were incubated with 10 nM Aβ42 for 2 hours, and the amount of Aβ42 in lysosomes was measured. The amounts of Aβ42 in lysosomes from squalestatin-treated neurons were significantly higher than the amounts of Aβ42 in lysosomes from control neurons (Figure 2D).

**Figure 1 Squalestatin increased the degradation of Aβ42.** (A) Immunoblot showing amyloid-beta (Aβ) monomers (M), dimers (D), and trimers (T) in conditioned media from 7PA2 cells (7PA2-CM) (1) and in Aβ-depleted 7PA2-CM (2). (B) Aβ monomers, dimers, and trimers eluted from a Superdex 75 PC column (separates proteins ranging from 3 to 70 kDa) loaded with concentrated 7PA2-CM. Values are mean Aβ42 of duplicates. (C) Neurons were pre-treated with control medium (●) or 200 nM squalestatin (○), pulsed with 7PA2-CM containing 10 nM Aβ42, and incubated for 1 to 5 days as shown. Values are mean Aβ42 remaining in neurons ± standard deviation (SD) from triplicate experiments performed four times (n = 12). (D) Neurons were pre-treated with control medium (●) or 200 nM squalestatin (○), pulsed with 100 nM synthetic Aβ42, and incubated for 1 to 5 days as shown. Values are mean Aβ42 in neurons ± SD from triplicate experiments performed four times (n = 12). (E) Neurons were pre-treated with control medium (●) or 200 nM squalestatin (○) and pulsed with 7PA2-CM containing Aβ42, as shown for 2 hours. Values are mean neuronal Aβ42 ± SD from triplicate experiments performed three times (n = 9). (F) Neurons, incubated with 7PA2-CM containing 10 nM Aβ42 for 2 days, were treated with control medium (●) or 200 nM squalestatin (○) for 24 hours. Values are the mean Aβ42 remaining in neurons ± SD from triplicate experiments performed three times (n = 9). *Concentrations of Aβ42 significantly less (P <0.05) than controls.
squalene (Table 1). Furthermore, the effect of squalostatin on the degradation of \( \beta_42 \) by neurons was reversed by the addition of squalene. When neurons incubated with 10 nM \( \beta_42 \) for 2 days were subsequently treated with combinations of squalostatin and squalene for 24 hours, the amounts of \( \beta_42 \) in neurons treated with 200 nM squalostatin and 5 \( \mu \)M squalene were significantly higher than in neurons treated with 200 nM squalostatin alone (8.9 nM \( \beta_42 \pm 0.8 \) compared with 2.4 nM \( \beta_42 \pm 0.6 \), \( n = 9 \), \( P < 0.01 \)).

### Phospholipase A2 and platelet-activating factor affect the degradation of \( \beta_42 \)

As \( \beta_42 \) activates cytoplasmic phospholipase A2 (cPLA2) [37-40], an enzyme that is implicated in tubule formation and intracellular trafficking [41-43], specifically within the trans-Golgi network [44], the effects of cPLA2 inhibitors on \( \beta_42 \) distribution were studied. Neurons were pulse with 7PA2-CM containing 10 nM \( \beta_42 \) for 2 hours and were washed, and cell extracts were collected at time points thereafter. Pre-treatment of neurons with cPLA2 inhibitors (1 \( \mu \)M AACOCF3 or MAFP) significantly reduced the half-life of \( \beta_42 \) in neurons (Figure 3A). As the activation of cPLA2 results in the production of prostaglandins and PAF, specific inhibitors/antagonists of these mediators were also tested. The half-life of \( \beta_42 \) was reduced in neurons pre-treated with PAF receptor antagonists (1 \( \mu \)M ginkgolide B or 1 \( \mu \)M Hexa-PAF) (Figure 3B) but not in neurons pre-treated with cyclo-oxygenase inhibitors (1 \( \mu \)M aspirin or 2 \( \mu \)M ibuprofen) that reduce the production of prostaglandins. In neurons pre-treated with ginkgolide B or Hexa-PAF, the half-life of \( \beta_42 \) was reduced to less than 24 hours. The addition of 1 \( \mu \)M Hexa-PAF to neurons that had been incubated with 10 nM \( \beta_42 \) for 2 days resulted in the increased degradation of \( \beta_42 \) (Figure 3C). \( \beta_42 \) was not detected in the supernatants collected from either control or treated neurons, indicating that it was not secreted. Such results suggest that PAF, produced in response to Aβ, regulates the trafficking and hence the degradation of \( \beta_42 \) in neurons. In support of this hypothesis, we found that the addition of 1 \( \mu \)M PAF reversed the effects of the cPLA2 inhibitor (1 \( \mu \)M Hexa-PAF) (Figure 3D). Experiments performed using synthetic \( \beta_1-42 \) showed that it had a half-life of approximately 24 hours in neurons pre-treated with Hexa-PAF (Figure 3E).

### Hexa-PAF altered the distribution of \( \beta_42 \) in neurons

As the effects of Hexa-PAF on the neuronal degradation of \( \beta_42 \) were similar to those of squalostatin, its effects upon cellular distribution of \( \beta_42 \) were studied. After the addition of 10 nM \( \beta_42 \) for 2 hours, we found no significant differences in the amounts of cell-associated \( \beta_42 \) between control and Hexa-PAF-treated neurons (9.1 nM \( \beta_42 \pm 0.7 \) compared with 8.7 ± 1, \( n = 9 \), \( P = 0.32 \)). However, pre-treatment of neurons with 1 \( \mu \)M Hexa-PAF or 1 \( \mu \)M ginkgolide B significantly reduced the amount of \( \beta_42 \) found within DRMs (Figure 4A). Since the detergent

---

**Table 1** Squalene reversed the effects of squalostatin upon \( \beta_42 \) trafficking

| Concentration of \( \beta_42 \), nM | 
|-------------------------------|---|
|                               | Cell extracts | DRMs | Lysosomes |
| Control                       | 8.7 ± 0.7     | 8.4 ± 0.6 | 0.4 ± 0.2 |
| Squalostatin                  | 8.7 ± 1       | 2.4 ± 0.6 | 2.8 ± 0.5 |
| Squalostatin + squalene       | 8.5 ± 0.85    | 8 ± 0.4  | 0.5 ± 0.2 |

Neurons were pre-treated with 200 nM squalostatin, 5 \( \mu \)M squalene, or a mixture of squalostatin and squalene and then incubated with conditioned media from 7PA2 cells (7PA2-CM) containing 10 nM \( \beta_42 \) for 2 hours. The concentrations of \( \beta_42 \) in whole cell extracts, detergent-resistant membranes (DRMs) (lipid rafts), and lysosomes were measured by enzyme-linked immunosorbent assay. Values are the mean concentration of \( \beta_42 \) ± standard deviation from triplicate experiments performed three times (\( n = 9 \)). *Amounts of \( \beta_42 \) significantly lower than in control cells. **Amounts of \( \beta_42 \) significantly higher than in control cells.
solubility assay is a crude test of membrane targeting, neurons were incubated for 2 hours with 10 nM Aβ_{42} and membranes were separated on sucrose density gradients.
In control neurons, most of the Aβ42 was found in low-density membrane fractions. In neurons pre-treated with 1 μM Hexa-PAF, less of the Aβ42 was found within low-density fractions (Figure 4B). Although treatment with 1 μM Hexa-PAF did not affect the amount of the LAMP-1 found in neurons (Figure 4C), the amounts of Aβ42 in lysosomes from neurons pre-treated with Hexa-PAF or ginkgolide B were significantly higher than the amounts of Aβ42 in lysosomes from control neurons (Figure 4D).

The effects of Hexa-PAF are not reversed by squalene
The similar effects of squalestatin and Hexa-PAF upon Aβ42 trafficking suggested that Hexa-PAF may affect cholesterol synthesis. However, treatment with either 1 μM PAF or 1 μM Hexa-PAF did not significantly affect the amounts of cholesterol in neurons and the addition of 5 μM squalene did not reverse the effects of Hexa-PAF upon the targeting of Aβ42 to DRMs or lysosomes (Table 2) nor alter the half-life of Aβ42 in Hexa-PAF-treated neurons, indicating that Hexa-PAF did not affect cholesterol synthesis. Next, we explored the hypothesis that PAF increased cholesterol in specific cellular compartments. We sought to identify such compartments by separating organelles upon density gradients. PAF receptors were found in high concentrations in fractions 6 to 8 (Figure 5A), fractions that also contained Grp78, a marker of the ER. These fractions were subsequently pooled and incubated with or without PAF. The addition of 2 μM PAF caused a significant increase in cholesterol (Figure 5B). The PAF-induced increase in cholesterol in these fractions was not blocked by the inclusion of 200 nM squalestatin, indicating that PAF was not stimulating cholesterol synthesis. Conversely, the addition of PAF significantly reduced the amounts of cholesterol esters in ER fractions (Figure 5C).

Table 2 Squalene does not reverse the effects of Hexa-PAF upon Aβ42 trafficking

| Concentration of Aβ42, nM | Cell extracts | DRMs | Lysosomes |
|--------------------------|---------------|------|-----------|
| Control                  | 8.7 ± 0.7     | 8.4 ± 0.6 | 0.4 ± 0.2 |
| Hexa-PAF                 | 8.5 ± 1.2     | 2.5 ± 0.9 | 3 ± 0.6   |
| Squalene                 | 8.5 ± 0.9     | 8 ± 0.4  | 0.5 ± 0.2 |
| Hexa-PAF + squalene      | 8.8 ± 0.6     | 2.8 ± 0.9 | 3 ± 0.4   |

Neurons were pre-treated with 1 μM Hexa-PAF, 5 μM squalene, or a mixture of Hexa-PAF and squalene and then incubated with conditioned media from 7PA2 cells (7PA2-CM) containing 10 nM Aβ42 for 2 hours. The amounts of Aβ42 in whole cell extracts, detergent-resistant membranes (DRMs) (lipid rafts), and lysosomes were measured by enzyme-linked immunosorbent assay. Values are the mean concentration of Aβ42 ± standard deviation from triplicate experiments performed three times (n = 9). *Amounts of Aβ42 significantly lower than in control cells. aAmounts of Aβ42 significantly higher than in control cells. Hexa-PAF, 1-O-hexadecyl-2-acetyl-sn-glycerol-3-phospho- (N,N,N-trimethyl)-hexanolamine.

Platelet-activating factor stimulates the release of cholesterol from stores of cholesterol esters
To determine the source of the PAF-induced increase in cholesterol, other methods of cholesterol regulation were explored. The amounts of cholesterol within cells is tightly controlled via a mixture of synthesis, uptake, and efflux and by esterification of cholesterol [45]. The cholesterol ester cycle involves the esterification of cholesterol by ACAT and the storage of cholesterol esters as cytoplasmic droplets [46]. Conversely, the hydrolysis of cholesterol esters results in the release of cholesterol from these stores. Thus, the cholesterol ester cycle helps maintain a constant level of cholesterol in cell membranes [46,47]. Our findings that that both ACAT and CEH were concentrated in the ER fractions along with PAF receptors (Figure 6A) suggested that PAF-induced activation of CEH released cholesterol. To explore the role of CEH in the trafficking of Aβ42, an inhibitor of CEH (DEUP) was used [48]. Treatment with 20 μM DEUP did not significantly affect total neuronal...
increase in cholesterol (Figure 6B) and the PAF-induced reduction in cholesterol esters (Figure 6C). Pre-treatment of neurons with 20 μM DEUP did not alter the amount of Aβ42 that bound to neurons, but reduced the amounts of Aβ42 in DRMs and increased the amounts of Aβ42 in lysosomes (Table 3). As a consequence, the half-life of Aβ42 in DEUP-treated cells was reduced to approximately 24 hours (Figure 6D). Pre-treatment of neurons with 20 μM DEUP also reduced the half-life of synthetic Aβ1-42 to approximately 24 hours (Figure 6E). Notably, these effects of DEUP were not reversed by the inclusion of 5 μM squalene, indicating that they were not mediated by inhibition of cholesterol synthesis. Collectively these results suggest that CEH regulates the hydrolysis of cholesterol esters in the ER which is involved in the trafficking of Aβ42.

Discussion

This study showed that Aβ42 taken up by cultured neurons was found predominantly within lipid rafts, traffics via a pathway that avoids the lysosomes and consequently was cleared slowly. We hypothesize that the slow clearance of Aβ42 from neurons is a significant factor in the accumulation of Aβ42 within the brain and leads to synapse damage and dementia in AD. Critically, we show that these properties are dependent upon Aβ42-induced activation of PLA2, the production of PAF, and the activation of CEH, the blockade of which alters the distribution of Aβ42 in neurons and greatly increased its degradation.

This study used nanomolar concentrations of Aβ which did not affect the viability of neurons and which were similar to those found in the cerebrospinal fluid [49,50] or in soluble brain extracts from patients with AD [51-53]. In control neurons, most of the Aβ was found within rafts, an observation consistent with reports that Aβ in the brain is found within cholesterol-dense membrane rafts [19-21]. Reports that Aβ affects cholesterol levels (552 ng cholesterol ± 34 compared with 519 ng ± 48, n = 6, P = 0.26). However, pre-treatment of ER fractions with 20 μM DEUP blocked the PAF-induced

**Figure 6** Platelet-activating factor (PAF) causes the release of cholesterol in the endoplasmic reticulum (ER). (A) Neuronal extracts were separated by density gradient centrifugation and analyzed for cholesterol ester hydrolase (CEH) (●) and anti-acyl-coenzyme A cholesterol acyltransferase (ACAT) (○). (B) The amount of cholesterol in ER fractions pre-treated with control medium (●), 20 μM diethylumbelliferyl phosphate (DEUP), or 2 μM PAF or pre-treated with DEUP and incubated with PAF (●). Values are mean ± standard deviation (SD) from triplicate experiments performed three times (n = 9). *Significantly less (P <0.05) cholesterol than ER fractions incubated with PAF. (C) The amount of cholesterol esters in ER fractions incubated with control medium (●), 20 μM DEUP, or 2 μM PAF or pre-treated with DEUP and incubated with PAF (●). Values are mean ± SD from triplicate experiments performed three times (n = 9). *Significantly more (P <0.05) cholesterol esters than ER fractions incubated with PAF. (D) Neurons treated with control medium (●) or 20 μM DEUP (○) were pulsed with conditioned media from 7PA2 cells (7PA2-CM) containing 10 nM Aβ42 and incubated for 1 to 5 days as shown. Values are mean Aβ42 ± SD from triplicate experiments performed four times (n = 12). (E) The amount of Aβ42 in neurons pre-treated with control medium (●) or 20 μM DEUP (○), pulsed with 100 nM synthetic Aβ42, and incubated for 1 to 5 days. Values are mean Aβ42 ± SD from triplicate experiments performed four times (n = 12).

**Table 3** Squalene does not reverse the effects of DEUP upon Aβ42 trafficking

| Concentration of Aβ42, nM | Cell extracts | DRMs | Lysosomes |
|--------------------------|---------------|------|-----------|
| Control                  | 8.7 ± 0.7     | 8.4 ± 0.6 | 0.4 ± 0.2 |
| DEUP                     | 8.6 ± 0.9     | 2.2 ± 0.7a | 2.8 ± 0.3b |
| Squalene                 | 8.5 ± 0.9     | 8 ± 0.4   | 0.5 ± 0.2 |
| DEUP + squalene          | 8.9 ± 0.8     | 2 ± 0.6a  | 2.7 ± 0.2b |

Neurons were pre-treated with 20 μM diethylumbelliferyl phosphate (DEUP), 5 μM squalene, or a mixture of DEUP and squalene and then incubated with conditioned media from 7PA2 cells (7PA2-CM) containing 10 nM Aβ42 for 2 hours. The amounts of Aβ42 in whole cell extracts, detergent-resistant membranes (DRMs) (lipid rafts), and lysosomes were measured by enzyme-linked immunosorbent assay. Values are the mean concentration of Aβ42 ± standard deviation from triplicate experiments performed three times (n = 9). *Amounts of Aβ42 significantly less than in control cells. aAmounts of Aβ42 significantly higher than in control cells.
cellular cholesterol homeostasis [54-56] suggested that Aβ modifies the biochemistry of cell membranes and thus creates the rafts that are responsible for its trafficking. The targeting of Aβ42 to rafts may have important biological consequences as many of the proteins that are targeted to rafts avoid the classic endocytic trafficking pathway that ends in the lysosomes [22,57]. Our observations were compatible with Aβ42 trafficking via a recycling pathway in neurons as little Aβ42 was found within lysosomes and consequently Aβ42 had a long half-life (over 5 days) in these neuronal cultures. Here, we show that the trafficking of Aβ42 within neurons could be affected by inhibiting cholesterol synthesis. Cholesterol has multiple effects upon cells, including altering membrane fluidity, protein trafficking, endocytosis, and exocytosis [58]. More specifically, cholesterol is important for the formation and function of membrane rafts, and in cholesterol-depleted neurons, most of the Aβ42 was excluded from such rafts. Consequently, more Aβ42 was found within lysosomes and the half-life of Aβ42 was reduced from over 5 days in untreated neurons to less than 24 hours in squalestatin-treated neurons. Squalestatin was used because it inhibits squalene synthetase and reduces cholesterol production without affecting the production of the isoprenoids [27]. However, because squalestatin does not cross the blood-brain barrier, it does not have clinical application. Similar results were obtained in neurons treated with simvastatin, a cholesterol synthesis inhibitor that crosses the blood-brain barrier (data not shown). Simvastatin is widely used clinically and has been reported to reduce cholesterol levels within the brain [59,60].

Since cholesterol synthesis inhibitors affect many cholesterol-sensitive processes, we sought to find a compound with a more selective effect on rafts containing Aβ. Here, we showed that inhibitors of cPLA2, an enzyme that is implicated in tubule formation and intracellular trafficking [41-44], also affected Aβ12 distribution. The activation of cPLA2 is the first step in the production of PAF [61,62]. PAF is produced in neurons incubated with Aβ42, and the amounts of PAF were elevated in both the temporal cortex of patients with AD and in murine AD models [63]. Our study suggested that the effects of cPLA2 inhibitors on Aβ42 distribution were mediated by a reduction in PAF production; not only did PAF antagonists have similar effects as cPLA2 inhibitors, but PAF also reversed the effects of cPLA2 inhibitors on Aβ42 distribution and degradation.

Treating neurons with PLA2 inhibitors, PAF antagonists, or PAF did not affect total cellular cholesterol concentrations, suggesting that these drugs did not affect cholesterol synthesis. PAF receptors were concentrated in the ER, and PAF increased cholesterol concentrations within ER fractions. Our studies are consistent with the hypothesis that local cholesterol concentrations within the ER affect the formation and functional rafts involved in the trafficking of Aβ42. Consequently, PAF antagonists had similar effects to squalestatin on the trafficking of Aβ42 in that they reduced the amount of Aβ42 within rafts. PAF is involved in endocytosis and endosome formation [64,65], and the blockade of PAF receptors may block the formation of endocytic structures involved in the trafficking or Aβ42. In neurons pre-treated with PAF receptor antagonists, more Aβ42 was detected within lysosomes, sites of protein degradation [66], and the half-life of Aβ42 was reduced to less than 24 hours.

Notably, the PAF-induced increase in cholesterol was accompanied by reduced cholesterol esters, suggesting that cholesterol was being released from stores of cholesterol esters. The enzymes involved in the cholesterol ester cycle, ACAT and CEH, were also concentrated in the ER [67], and the PAF-induced increase in cholesterol was blocked by inhibition of CEH. The role of CEH in Aβ42 metabolism was demonstrated by using an inhibitor of CEH [48], which greatly increased the degradation of Aβ42 in a similar manner as PAF antagonists or squalestatin. Collectively these results indicate that PAF regulates the deacylation of cholesterol esters in the ER, freeing cholesterol that affects the formation and function of rafts which are involved in the trafficking of Aβ42.

Figure 7 Platelet-activating factor (PAF)-mediated hydrolysis of cholesterol esters stabilizes amyloid-beta (Aβ)-containing lipid rafts. Schematic demonstrating the putative mechanism regulating the formation of Aβ-containing rafts. In this theory, Aβ42 activates cPLA2, resulting in the production of PAF. PAF activates cholesterol ester hydrolase (CEH) and the release of cholesterol from stores of cholesterol esters, which stabilizes Aβ42 in rafts. Inhibition of cPLA2 (arachidonyl trifluoro-methyl ketone, or AACOCF3), antagonism of the PAF receptors (Hexa-PAF), or inhibition of CEH (diethylumbelliferone phosphate, is DEUP) reduces the cholesterol concentrations in the endoplasmic reticulum (ER). cPLA2 is cytoplasmic phospholipase A2, Hexa-PAF, 1-O-hexadecyl-2-acetyl-sn-glycerol-3-phospho-(N,N,N-trimethyl)-hexanolamine.
Conclusions
In summary, these results support the hypothesis that Aβ_{42}-induced activation of PLA₂ leads to the production of PAF which releases cholesterol from cholesterol esters. The cholesterol helps stabilize Aβ_{42} in rafts which traffic via a recycling pathway that avoids the lysosomes. Thus, PAF receptor antagonists that reduce the release of cholesterol affect the rafts that direct Aβ_{42} into the recycling pathway as summarized in Figure 7. Consequently, in these neurons, the half-life of Aβ_{42} was greatly reduced. In neurons treated with cholesterol synthesis inhibitors, PAF antagonists, or CEH inhibitors, the trafficking of Aβ_{42} is altered so that Aβ_{42} was found outside rafts, was targeted to lysosomes, and rapidly degraded. The novel observation that the activation of specific signaling pathways controls the trafficking and degradation of Aβ_{42} may aid the development of drugs to delay the progression of AD.

Abbreviations
7PA2-CM: conditioned media from 7PA2 cells; A2OCCF₃: arachidonyl trifluoromethyl ketone; ACAT: acyl-coenzyme A cholesterol acyltransferase; AD: Alzheimer’s disease; Aβ: amyloid-beta; CHER: cholesterol ester hydrolase; CM: conditioned media; cPLA₂: cytoplasmic phospholipase A₂; DEUP: diethylumbelliferyl phosphate; DRM: detergent-resistant membrane; ELISA: enzyme-linked immunosorbent assay; ER: endoplasmic reticulum; Hexa-PAF: 1-O-hexadecyl-2-acetyl-sn-glycero-3-phospho-(N,N,N-trimethyl)-hexanoline; LAMP-1: lysosome-associated membrane protein 1; mAb: monoclonal antibody; MAFP: methyl arachidonyl fluorophosphonate; PAF: platelet-activating factor; PBS: phosphate-buffered saline; PLA₂: phospholipase A₂; PVP: polyvinylpyrrolidone; SDS: sodium dodecyl sulphate.

Competing interests
The authors declare that they have no competing interests.

Authors’ contributions
W and CS contributed to data collection and analysis and to drafting and critical revision of manuscript. CB contributed to conception and design, data collection and analysis, and manuscript writing and revision. AW contributed to conception and design, and manuscript writing. All authors read and approved the final manuscript.

Acknowledgments
This work was supported by the Royal Veterinary College BioVetinary Science research project funds. We thank Professor Edward Koo for supplying 7PA2 cells. This work was supported by the Royal Veterinary College BioVetinary Science.

References
1. Vassar R, Citron M: Ab-generating enzymes: recent advances in b and g-secretase research. Neuron 2000, 27:419–422.
2. Georgopapadaki DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, Mirkin CA: Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease. Proc Natl Acad Sci U S A 2005, 102:2273–2276.
3. De Felice FG, Wu D, Lambert MP, Fernandez SJ, Velasco PT, Lacor PN, Bigio EH, Jerecic J, Acton PJ, Shughrue PJ, Chen-Dodson E, Kinney GG, Klein WL.
4. Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by Aβ oligomers. Neurobiol Aging 2008, 29:1334–1347.
5. Selkoe DJ: Alzheimer’s disease: a central role for amyloid. J Neuropath Exp Neurol 1994, 53:438–447.
6. Lambert MP, Barlow AH, Chrony BA, Edwards C, Freed R, Liosatos M, Morgan TE, Rozovsky I, Trommer B, Voia KL, Wals P, Zhang C, Finch CE, Krafft GA, Klein WL. Diffusible, nonfibrillar ligands derived from Aβ_{42} are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A 1998, 95:6448–6453.
7. Klein WL, Krafft GA, Finch CE. Targeting small Ab oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci 2001, 24:219–224.
8. Gouras GK, Tampellini D, Takahashi RH, Capetillo-Zarate E. Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer’s disease. Acta Neuropathol 2010, 119:523–541.
9. Takahashi RH, Milner TA, Li F, Nam EE, Edgar MA, Yamaguchi H, Beal MF, Xu H, Greenberg P, Gouras GK. Intraneuronal Alzheimer Ab$_{42}$ accumulates in multisynaptic bodies and is associated with synaptic pathology. Am J Pathol 2002, 161:1869–1879.
10. Iwata N, Tsubuki S, Takaki Y, Shirotani K, Lu B, Gerard NP, Gerard C, Hama E, Lee H-J, Saito TC. Metabolic regulation of brain abeta by neprilysin. Science 2001, 292:1550–1552.
11. Miller BC, Eckman EA, Sambamurti K, Dobbs N, Chow KM, Eckman CB, Hersh LB, Thiele DL. Amyloid-b peptide levels in brain are inversely correlated with insulin activity levels in vivo. Proc Natl Acad Sci U S A 2003, 100:6221–6226.
12. Sun B, Zhou Y, Halabisky B, Lo I, Cho SH, Mueller-Steiner S, Devidze N, Wang X, Grubb A, Lan G. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer’s disease. Neuron 2008, 60:247–257.
13. Yamin R, Zhao C, O’Connor P, McKeever A, Abraham C. Amyloid peptide hydrolase degrades monomeric and oligomeric amyloid-beta peptide. Mol Neurodegener 2009, 4:33.
14. Shankar G, Walsh D. Alzheimer’s disease: synaptic dysfunction and A beta. Mol Neurodegener 2009, 4:48.
15. Manzoni C, Colombo L, Messa M, Cantu L, Del Favero E, Salmina M. Overcoming synthetic A beta peptide aging: a new approach to an age-old problem. Amyloid 2009, 16:71–80.
16. Podrinya MB, Ostaszewski BL, Squazzo SL, Koo EH, Rydell RE, Teplow DB, Selkoe DJ. Aggregation of secreted amyloid b-protein into sodium dodecyl sulfate-stable oligomers in cell culture. J Biol Chem 1995, 270:9564–9570.
17. Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, Sabatini BL. Natural Oligomers of the alzheimer amyloid-b protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 2007, 27:2886–2897.
18. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ. Amyloid-b peptide dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 2008, 14:837–842.
19. Walsh DM, Selkoe DJ. Ab oligomers – a decade of discovery. J Neurochem 2007, 101:1172–1184.
20. Oshima N, Morishima-Kawashima M, Yamaguchi H, Yoshimura M, Sugihara S, Khan K, Games D, Schenk D, Iwata Y. Accumulation of amyloid b-protein in the low-density membrane domain accurately reflects the extent of (beta)amyloid deposition in the brain. Am J Pathol 2001, 158:2209–2218.
21. Kawarabayashi T, Shoji M, Younkin LH, Wen-Lang L, Dickson DW, Murakami T, Matsubara E, Abe K, Ashe KH, Younkin SG. Dimeric amyloid b protein rapidly accumulates in lipid rafts followed by apolipoprotein E and phosphorylated tau accumulation in the Tg2576 mouse model of Alzheimer’s disease. J Neurosci 2004, 24:3801–3809.
22. Lee SJ, Liyanage U, Bickel PE, Xia W, Lansbury PT Jr, Kosik KS. A detergent-insoluble membrane compartment contains A beta in vivo. Nat Med 1998, 4:730–734.
23. Nabi IR, Le PJ. Caveolae/raft-dependent endocytosis. J Cell Biol 2003, 161:673–677.
24. Nichols B. Amyloidoses and endocytosis of lipid rafts. J Cell Sci 2003, 116:407–4714.
25. Hancock JF. Lipid rafts: contentious only from simplistic standpoints. Nat Rev Mol Cell Biol 2006, 7:456–462.
26. Pike LJ. Lipid rafts: heterogeneity on the high seas. Biochem J 2004, 378:281–292.
26. Rajendran L, Simons K: Lipid rafts and membrane dynamics. J Cell Sci 2005, 118:1099–1102.

27. Baxter A, Fitzgerald BJ, Hutson JL, McCarthy AD, Mottram JM, Ross BC, Sapra M, Snowden MA, Watson NS, Williams RJ: Squeaslatin 1, a potent inhibitor of squalene synthase, which lowers serum cholesterol in vivo. J Biol Chem 1992, 267:17105–17108.

28. London E, Brown DA: Insolubility of lipids in Triton X-100: physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim Biophys Acta 2000, 1508:182–195.

29. Maxfield FR, Tabas I: Role of cholesterol and lipid organization in disease. Nature 2005, 438:612–621.

30. Shobab LA, Huang GY, Feldman HT: Cholesterol in Alzheimer's disease. Lancet Neurol 2005, 4:841–852.

31. Bate C, Williams A: Squeaslatin promotes neurons and reduces the activation of cytoplasmic phospholipase A2 by Aβ. J Neuropharmacology 2007, 53:222–231.

32. Bate C, Salmina M, Diomede L, Williams A: Squeaslatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem 2004, 279:14936–14943.

33. Barrantes FJ: Cholesterol effects on nicotinic acetylcholine receptor. J Neurochem 2007, 103:78–80.

34. Williamson R, Usardi A, Hanger DP, Anderton BH: Platelet-activating factor antagonists. Biochim Biophys Acta 2000, 1483:344–358.

35. Phair RD, Lippincott-Schwartz J: Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol Biol Cell 2002, 13:238–250.

36. De Figueiredo P, Doody A, Polizotto RS, Drecktrah D, Wood S, Banta M, Simons K, Ikonen E: How cells handle cholesterol. Science 2000, 286:214–221.

37. Chang TY, Chang CCY, Cheng D: Acyl-coenzyme A:cholesterol acyltransferase. Annu Rev Plant Physiol Plant Mol Biol 1997, 48:613–638.

38. Ikonen E: Cellular cholesterol trafficking and compartmentalization. Nat Rev Mol Cell Biol 2008, 9:125–138.

39. Cocce P, Freeman D: A cholesterol-ester hydrolase inhibitor blocks cholesterol translocation into the mitochondria of MA-10 Leydig tumor cells. Endocrinology 1992, 131:2972–2978.

40. Biddi M, Mollenhauer B, Esselmann H, Lewczuk P, Klaflh H-W, Sparbi K, Smirnov A, Cepck L, Trexkenwalter C, Ruther E, Kornhier J, Otto M, Wittfang J: CSF amyloid-β-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 2006, 129:1177–1187.

41. Mehta PD, Pirttila T, Mehta SP, Sersen EA, Aisen PS, Wisneiwski HM: Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 2000, 57:100–105.

42. Robertson F, Sheppard FR, Moore EE, Mierau GW, Elzi DJ, Silliman CC, Robertson P, Sheppard FR, Moore EE, Mierau GW, Elzi DJ, Silliman CC: Platelet-activating factor-induced actin bundle formation.

43. Chandra R, Chakraborty A, De D, Ramesh T: Cerebrospinal fluid β-amylloid concentrations in Alzheimer disease. Neurology 2007, 68:205–213.

44. Phair RD, Lippincott-Schwartz J: Caveolae are highly immobile plasma membrane microdomains, which are not involved in constitutive endocytic trafficking. Mol Biol Cell 2002, 13:238–250.

45. Nichols BJ, Kenworthy AK, Polischuk RS, Lodge R, Roberts TH, Hirschberg K, Pharr RD, Lippincott-Schwartz J: Rapid cycling of lipid raft markers between the cell surface and Golgi complex. J Cell Biol 2001, 153:529–541.

46. Thelen KM, Rentzsch KM, Gutteck U, Hererin M, Ollin M, Andersson U, von Eckardstein A, Bjoerkhem I, Luttahnn D: Brain cholesterol synthesis in mice is affected by high dose of simvastatin but not of pravastatin. J Pharmacol Exp Ther 2005, 316:1146–1152.

47. Kirsch C, Eckert GP, Mueller WE: Statin effects on cholesterol micro-domains in brain plasma membranes. Biochim Bio phys Acta 2003, 160:1019–1059.

48. Bate C, Salmina M, Diomede L, Williams A: Squeaslatin cures prion-infected neurons and protects against prion neurotoxicity. J Biol Chem 2004, 279:14936–14943.

49. Barrantes FJ: Cholesterol effects on nicotinic acetylcholine receptor. J Neurochem 2007, 103:78–80.